

Form PTO 1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 5-93)		ATTORNEY'S DOCKET NUMBER P32374
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/049227
INTERNATIONAL APPLICATION NO. PCT/EP00/07295	INTERNATIONAL FILING DATE 27 July 2000	PRIORITY DATE CLAIMED 30 July 1999
TITLE OF INVENTION Multi-Component Pharmaceutical Dosage Form		
APPLICANT(S) FOR DO/EO/US Allan J. CLARKE, Teodore FONIO, Geoffrey Arthur HARRIS, Ronald KIFT, Donald LIGHTFOOT, Shane MCGINLEY, Thomas OFSHARICK, Margaret Mary SZYMCAK		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98; and Form PTO-1449.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☒ Please amend the specification by inserting before the first line the sentence: This is a §371 national stage entry of International Application PCT/EP00/07295, filed 27 July 2000.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☒ An Abstract on a separate sheet of paper.
19. ☐ Other items or information.


10/13/2007 09:30:30
 10/13 Rec'd PCT/PTO 30 JAN 2007

US APPLICATION NO (if known see 37 CFR 1.50) 10/13/2007		INTERNATIONAL APPLICATION NO PCT/EP00/07295		ATTORNEYS DOCKET NO P32374	
20. [X] The following fees are submitted.				CALCULATIONS PTO USE ONLY	
Basic National Fee (37 C.F.R. 1.492(a)(1)-(5)):				\$890.00	
Search Report has been prepared by the EPO or JPO\$890.00					
International Preliminary Examination Fee paid to USPTO (37 CFR 1.492)\$710.00					
No International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) but international search fee paid to USPTO (37 CFR 1.445(a)(2))\$740.00					
Neither International Preliminary Examination Fee (37 CFR 1.492) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$1,040.00					
International Preliminary Examination Fee paid to USPTO (37 CFR 1.492) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$0.00	
Claims	Number Filed	Number Extra	Rate		
Total claims	32 - 20 =	12	12 x \$18.00	\$216.00	
Independent claims	4 - 3 =	1	1 x \$84.00	\$84.00	
Multiple dependent claims (if applicable)			+ \$280.00	\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$1190.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$1190.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)) +				\$	
TOTAL NATIONAL FEE =				\$1190.00	
				Amount to be refunded	\$
				charged	\$1190.00

- a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 19-2570 in the amount of **\$1190.00** to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-2570. A duplicate copy of this sheet is enclosed.
- d. ☒ General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extension of time relating to this application (37 CFR 1.136 (a)(3)).

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
 GLAXOSMITHKLINE
 Corporate Intellectual Property - UW2220
 P.O. Box 1539
 King of Prussia, PA 19406-0939
 Phone (610) 270-5017
 Facsimile (610) 270-5090


 SIGNATURE
 Dara L. Dinner
 NAME
 33,680
 REGISTRATION NO

EXPRESS MAIL CERTIFICATE: EL737849704US
DATE OF MAILING: 30 January 2002

107/049227

JG13 Rec'd PCT/PTO 30 JAN 2002

PATENT

ATTORNEY'S DOCKET NUMBER **P32374**

TRANSMITTAL LETTER TO THE U.S. DESIGNATED OFFICE
(DO/US) - ENTRY INTO NATIONAL STAGE UNDER 35 USC 371

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP00/07295	27 July 2000	30 July 1999

TITLE OF INVENTION

Multi-Component Pharmaceutical Dosage Form

APPLICANT(S) FOR DO/US

**Allan J. CLARKE, Teodore FONIO, Geoffrey Arthur HARRIS, Ronald KIFT,
Donald LIGHTFOOT, Shane MCGINLEY, Thomas OFSHARICK,
Margaret Mary SZYMCZAK**

Box PCT

Commissioner of Patents and Trademarks

Washington, D.C. 20231

ATTENTION: DO/US

PRELIMINARY AMENDMENT

Dear Sir:

Preliminary to calculation of the filing fees and examination of the above noted application, entrance of the following remarks and amendments into the record is respectfully requested.

In the Claims:

Please cancel claims 2 to 37.

Please add the following claims:

38.(new) A multi-component pharmaceutical dosage form which comprises a plurality of sub-units, each sub-unit being selected from: a drug substance-containing capsule compartment which is soluble or disintegrable in a patient's gastro-intestinal environment for release of the drug substance contained in the capsule compartment, and a solid matrix comprising a polymer and containing a drug substance, the polymer being soluble, dispersible or disintegrable in a patient's gastro-intestinal environment for release of the drug substance contained in the solid matrix, and in which the sub-units are welded together in an assembled dosage form.

39.(new) A multi-component pharmaceutical dosage form according to Claim 38 wherein the sub-units comprise a plurality of drug substance-containing capsule compartments adjacent to one another and welded together, each of said adjacent capsule compartments being soluble or disintegrable in a patient's gastro-intestinal environment, the drug substances contained in each of said adjacent capsule compartments being physically separated from the drug substance contained in at least one adjacent, drug substance-containing, capsule compartment by a wall made of a pharmaceutically acceptable polymer material.

40.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least one of the sub-units is a solid matrix comprising a polymer and containing a drug substance, the polymer being soluble, dispersible or disintegrable in a patient's gastro-intestinal environment.

41.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least one of the sub-units is a solid matrix comprising a polymer and containing a drug substance, the polymer being soluble, dispersible or disintegrable in a patient's gastro-intestinal environment, and at least one of the other sub-units is a drug substance-containing capsule compartment which is soluble or disintegrable in a patient's gastro-intestinal environment.

42.(new) A multi-component pharmaceutical dosage form according to claim 38 in which the sub-units are held together in an assembled dosage form by one or more welds from the group consisting of thermal welds, inductive welds and ultrasonic welds.

43.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least two adjacent sub-units are connected together by one or more ultrasonic welds.

44.(new) A multi-component pharmaceutical dosage form according to claim 38 in which two adjacent sub-units are connected by a linker unit and in which at least one of said two adjacent sub-units is connected to the linker unit by one or more ultrasonic welds.

45.(new) A multi-component pharmaceutical dosage form according to claim 38 in which each of two adjacent sub-units is a drug substance-containing capsule compartment which is soluble or disintegrable in a patient's gastro-intestinal

environment, in which said adjacent sub-units are connected by a linker unit and in which at least one of said two adjacent sub-units is connected to the linker unit by one or more ultrasonic welds.

46.(new) A multi-component pharmaceutical dosage form according to claim 38 in which each of two adjacent sub-units is a drug substance-containing capsule compartment which is soluble or disintegrable in a patient's gastro-intestinal environment, in which said adjacent sub-units are connected by a linker unit, in which at least one of said two adjacent sub-units is connected to the linker unit by one or more ultrasonic welds, and in which the wall thickness of said at least one of said adjacent sub-units is in the range of about 0.3 to 0.5 mm.

47.(new) A multi-component pharmaceutical dosage form according to claim 38 in which each of two adjacent sub-units is a drug substance-containing capsule compartment which is soluble or disintegrable in a patient's gastro-intestinal environment, in which said adjacent sub-units are connected by a linker unit, in which at least one of said two adjacent sub-units is connected to the linker unit by one or more ultrasonic welds, and in which said at least one of said two adjacent sub-units has a frusto-conical side wall gently tapering toward an end wall, the end wall having a flattened central portion and rounded edge connecting the flattened central portion to the frusto-conical side wall.

48.(new) A multi-component pharmaceutical dosage form according to claim 38 in which each of two adjacent sub-units is a drug substance-containing capsule compartment which is soluble or disintegrable in a patient's gastro-intestinal environment, in which said adjacent sub-units are connected by a linker unit, in which at least one of said two adjacent sub-units is connected to the linker unit by one or more ultrasonic welds, and in which said at least one of said two adjacent sub-units has a side wall and an end wall, the end wall having a flattened central portion and rounded edge connecting the flattened central portion to the side wall, the flattened central portion having a substantially planar outer surface over at least 5% of the outer surface area of the end wall.

49.(new) A multi-component pharmaceutical dosage form according to claim 38 in which two adjacent sub-units are connected by a linker unit, in which at least one of the two adjacent sub-units is connected to the linker unit by a connection comprising interlocking tenons and an ultrasonic shear joint.

50.(new) A multi-component pharmaceutical dosage form according to claim 38 in which two adjacent sub-units are connected by a linker unit, in which at least one of the two adjacent sub-units is connected to the linker unit by a connection comprising interlocking tenons and an ultrasonic shear joint, one of said interlocking tenons being a collapsed form of a tenon which was initially longer than the other of said interlocking tenons.

51.(new) A multi-component pharmaceutical dosage form according to claim 38 in which the sub-units are held together in an assembled dosage form by one or more welds, at least one said weld being supplemented by a mechanical interconnection.

52.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least one of said sub-units is formed with a first interconnecting part, and an adjacent one of said sub-units is formed with a second interconnecting part which mates in interconnecting relationship with said first interconnecting part.

53.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least one of said sub-units is formed with a socket, and an adjacent one of said sub-units is formed with projection which mates in interconnecting relationship with said socket.

54.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least one of said sub-units is a tub-shaped, drug substance-containing, capsule compartment which is soluble or disintegrable in a patient's gastro-intestinal environment, said tub-shaped capsule compartment having a base closed by a base wall, side walls extending from said base wall, and a mouth, and in which an adjacent one of said sub-units is formed with an element which mates in interconnecting relationship with said mouth and completes the enclosure of the drug substance within said tub-shaped capsule compartment.

55.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least one of said sub-units is a tub-shaped, drug substance-containing, capsule compartment which is soluble or disintegrable in a patient's gastro-intestinal environment, said tub-shaped capsule compartment having a base closed by a base wall, side walls extending from said base wall, and a mouth, and in which an adjacent one of said sub-units is formed with a plug which fits into said mouth and completes the enclosure of the drug substance within said tub-shaped capsule compartment.

56.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least one of said sub-units is a tub-shaped, drug substance-containing, capsule compartment which is soluble or disintegrable in a patient's gastro-intestinal environment, said tub-shaped capsule compartment having a base closed by a base wall, side walls extending from said base wall, and a mouth, and in which an adjacent one of said sub-units is formed with a cap which fits over said mouth and completes the enclosure of the drug substance within said tub-shaped capsule compartment.

57.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least one of said sub-units is a tub-shaped, drug substance-containing, capsule compartment which is soluble or disintegrable in a patient's gastro-intestinal environment, said tub-shaped capsule compartment having a base closed by a base wall, side walls extending from said base wall, and a mouth, in which an adjacent one of said sub-units is a solid matrix comprising a polymer and containing a drug substance, the polymer being soluble, dispersible or disintegrable in a patient's gastro-intestinal environment, and said solid matrix of said adjacent one of said sub-units is formed with an element which mates in interconnecting relationship with said mouth and completes the enclosure of the drug substance within said tub-shaped capsule compartment.

58.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least one of the sub-units is a drug substance-containing capsule compartment which is soluble or disintegrable in a patient's gastro-intestinal environment, and in which, said capsule compartment is welded to an adjacent one of said sub-units and closed by means independent of said adjacent one of said sub-units.

59.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least two adjacent sub-units are connected together by a linker unit, to which at least one of said adjacent sub-units is welded.

60.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least two adjacent sub-units are connected together by a linker unit, to which at least one of said adjacent sub-units is welded, the linker unit being in the form of a generally cylindrical body having a diameter to length ratio in the range of about 4:1 to 1.5:1 and having an end surface which is substantially planar over at least 50% of its area.

61.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least two adjacent sub-units are connected together by a linker unit, to which said adjacent sub-units are welded.

Int'l App. No.: PCT/EP00/07295

Int'l Filing Date: 27 July 2000

- 6 -

62.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least two adjacent sub-units are drug substance-containing capsule compartments having mouth openings facing each other, and having a linker unit with two oppositely facing plugs fitting into the mouth openings of the respective adjacent drug substance-containing capsule compartments and completing the enclosure of the drug substances in said adjacent drug substance-containing capsule compartments.

63.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least two adjacent sub-units are drug substance-containing capsule compartments having mouth openings facing each other, and having a linker unit with two oppositely facing plugs fitting into the mouth openings of the respective adjacent drug substance-containing capsule compartments and completing the enclosure of the drug substances in said adjacent drug substance-containing capsule compartments, the linker unit having two oppositely facing abutment surfaces, and the mouth opening of each of said adjacent sub-units having a rim engaged with one of said abutment surfaces.

64.(new) A multi-component pharmaceutical dosage form according to claim 38 in which at least two adjacent sub-units are drug substance-containing capsule compartments having mouth openings facing each other, and having a linker unit with two oppositely facing plugs fitting into the mouth openings of the respective adjacent drug substance-containing capsule compartments and completing the enclosure of the drug substances in said adjacent drug substance-containing capsule compartments, each plug being surrounded by an annular shoulder formed in the linker unit, and the mouth opening of each of said adjacent sub-units having a rim engaged with one of said shoulders.

65.(new) A multi-component pharmaceutical dosage form according to Claim 38 wherein the sub-units comprise at least two drug substance-containing capsule compartments having differing wall thicknesses, whereby the thinner-walled compartment is disrupted more rapidly than the thicker-walled compartment.

66.(new) A multi-component pharmaceutical dosage form according to Claim 38 wherein at least one of said sub-units is a drug substance-containing capsule compartment which is soluble or disintegrable in a patient's gastro-intestinal environment, a part of the last-mentioned compartment being weakened so that it dissolves preferentially.

67.(new) A set of multi-component dosage forms, each comprising a plurality of sub-units each sub-unit being selected from:

- (a) a drug substance-containing capsule compartment which is soluble or disintegrable in a patient's gastro-intestinal environment for release of the drug substance contained in the capsule compartment, and
 - (b) a solid matrix comprising a polymer and containing a drug substance, the polymer being soluble, dispersible or disintegrable in a patient's gastro-intestinal environment for release of the drug substance contained in the solid matrix,
- in which at least one of the dosage forms of the set comprises at least one said drug substance-containing capsule compartment and at least one other dosage form of the set comprises at least one said solid matrix, in which the drug substance-containing capsule compartment of said at least one of the dosage forms is interchangeable with said solid matrix of said at least one other dosage form, and in which at least prior to administration to a patient, the sub-units of each dosage form are welded together to provide an assembled dosage form.

68.(new) A process for manufacturing a dosage form comprising a pair of drug substance-containing capsule compartments which are soluble or disintegrable in a patient's gastro-intestinal environment for release of the drug substance contained therein and a linker arranged between said capsule compartments for connecting the compartments together and having plug portions inserted into the capsule compartments and completing the enclosure of the drug substances therein, the process comprising the steps of filling one of said capsule compartments with a drug substance through an open end of said one of said capsule compartments; inserting a first plug portion of a linker into said open end of said one of said capsule compartments; welding the linker to said one of said capsule compartments; filling the other of said capsule compartments with a drug substance through an open end of said other of said capsule compartments; inserting the other plug portion of the linker into said open end of said other of said capsule compartments; and welding the linker to said other of said capsule compartments.

REMARKS

This Preliminary Amendment is being made upon entry of International Application No. PCT/EP00/07295 in the U.S. §371 national phase of prosecution. Claim 2 to 37 have been deleted and claim 38 to 68 have been added. Claim 1 and 38 to 68 are in the application.

A marked version of the amended claims accompanies this paper.

An abstract on a separate sheet of paper accompanies this request.


Int'l App. No.: PCT/EP00/07295

Int'l Filing Date: 27 July 2000

- 8 -

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below. If any additional fees or charges are required by this paper the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,


Dara L. Dinner

Attorney for Applicant

Registration No. 33,680

GLAXOSMITHKLINE

Corporate Intellectual Property UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-5017

Facsimile (610) 270-5090

n:\dld\oa\us\32374\prelimamend.doc

Int'l App. No.: PCT/EP00/07295
Int'l Filing Date: 27 July 2000

- 9 -

MARKED UP VERSION OF CLAIMS TO SHOW CHANGES MADE

Claim 2 to 37 have been deleted.

Claim 38 to 68 have been added.

Int'l Filing Date: 27 July 2000

- 10 -

ABSTRACT

A multi-component pharmaceutical dosage form comprising a plurality of drug substance - containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.

MULTI-COMPONENT PHARMACEUTICAL DOSAGE FORM

10/049227

This invention relates to pharmaceutical formulations, being a dosage form comprising two or more connected sub-units, particularly for oral dosing.

Various types of pharmaceutical dosage form are known for oral dosing.

- 5 Pharmaceutical capsules are well known, generally being intended for oral dosing. Such capsules generally comprise an envelope wall of a pharmaceutically acceptable, e.g. orally ingestible, polymer material such as gelatin, although other materials for capsule walls, e.g. starch and cellulose based polymers are also known. Such capsules generally have soft walls made by making a film on a capsule
10 former, which is then allowed to dry. Rigid walled capsules made by injection moulding are also known, see for example US 4576284, US 4591475, US 4655840, US 4738724, US 4738817 and US 4790881 (all to Warner Lambert). These disclose specific constructions of capsules made of gelatin, starch and other polymers, and methods of making them by injection moulding of hydrophilic polymer - water
15 mixtures. US 4576284 specifically discloses such capsules provided with a cap which closes the capsule, and which is formed in situ on the filled capsule by moulding. US 4738724 discloses a wide range of rigid capsule shapes and parts.

- Multi-compartment capsules, including those of the type where each compartment has different drug release characteristics or for example contains a
20 different drug substance or formulation are also known, for example in US 4738724 (Warner-Lambert), US 5672359 (University of Kentucky), US 5443461 (Alza Corp.), WO 9516438 (Cortecs Ltd.), WO 9012567 (Helminthology Inst.), DE-A-3727894, BE 900950 (Warner Lambert), FR 2524311, NL 7610038 (Tapanhony NV), FR 28646 (Pluripharma), US 3228789 (Glassman), US 3186910 (Glassman)
25 among others. US 4738817 discloses a multicompartment capsule with a similar construction to those of US 3228789 and US 3186910, made of a water-plasticised gelatin.

- Pharmaceutical dosage forms are also known which comprise a matrix of a solid polymer, in which a drug substance is dispersed, embedded or dissolved as a
30 solid solution. Such matrixes may be formed by an injection moulding process. This technology is discussed in Cuff G, and Raouf F, Pharmaceutical Technology June 1998 p 96-106. Some specific formulations for such dosage forms are for

example disclosed in US 4,678,516; US 4,806,337; US 4,764,378; US 5,004,601; US 5,135,752; US 5,244,668; US 5,139,790; US 5,082,655 among others; in which a polyethylene glycol ("PEG") matrix is used and solid dosage forms are made by injection moulding.

5 The content of the above-mentioned background publications is incorporated herein by way of reference.

 It is an object of this invention to provide an alternative and improved pharmaceutical dosage form which provides inter alia greater flexibility in producing a dosage form adapted to a patient's specific administration requirement, and to ease of manufacture. Other objects and advantages of the invention will be
10 apparent from the following description.

 According to this invention a multi-component dosage form is provided which comprises a plurality of drug substance – containing sub-units each selected from capsule compartments which can release their drug substance in the gastro-
15 intestinal environment, and solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the polymer being soluble, dispersible or disintegrable in the patient's gastro-intestinal environment to thereby release the drug substance, the sub-units being connected together in the assembled dosage form and being retained together by the connection at least prior to administration
20 to a patient, wherein the connection is provided by a weld between parts of the assembled dosage form.

 The connectable nature of these sub-units advantageously enables various sub-units having different drug release characteristics and/or contents to be assembled and connected together to produce a dosage form. In a preferred form the
25 sub-units have common interchangeable interconnectable parts so that the sub-units of the invention may be assembled in various combinations using the same basic units of capsule compartments, solid sub-units, or of solid sub-units and capsule compartments. This can facilitate the rapid prototyping of a dosage form comprising a combination of different drug substances in respective sub-units, and/or
30 combinations of the same or different drug substances with different release characteristics, whilst simplifying the formulation procedure.

In a first embodiment of this invention the pharmaceutical dosage form comprises a plurality of capsule compartments each bounded and physically separated from at least one adjacent compartment by a wall made of a pharmaceutically acceptable polymer material, adjacent compartments being
5 connected together in the assembled dosage form and being retained together by the connection at least prior to administration to a patient, one or more of the compartments containing a drug substance, and wherein the connection is provided by a weld between parts of the assembled dosage form, suitably between immediately adjacent parts.

10 Suitably in the assembled dosage form of this first embodiment there are at least two, for example three, such capsule compartments. Three or more such compartments may be linearly disposed in the assembled dosage form, e.g. in an arrangement comprising two end compartments at opposite ends of the line, and one or more intermediate compartments. Suitably there may be two such capsule
15 compartments.

In a second embodiment of this invention the pharmaceutical dosage form comprises a plurality of drug-containing sub-units connected together in the assembled dosage form and being retained together by the connection at least prior to administration to a patient, at least one of the sub-units being a solid sub-unit
20 comprising a solid matrix of a polymer which contains a drug substance, the polymer being soluble, dispersible or disintegrable in the patient's gastro-intestinal environment to thereby release the drug substance, and wherein the connection is provided by a weld between parts of the assembled dosage form.

In one form of this second embodiment all of the sub-units in the dosage
25 form of this invention may be solid sub-units, e.g. two or more such solid sub-units, e.g. three such solid sub-units.

In another form of this second embodiment, one or more of the sub-units comprise a solid sub-unit, and one or more of the other sub-units may comprises a capsule compartment bounded by a wall made of a pharmaceutically acceptable
30 polymer material, one or more of the said capsule compartments containing a drug substance.

Suitably in the assembled dosage form there are at least two, for example three or more, e.g. four sub units. Such an assembled dosage form may comprise three or four sub-units comprising one, two or three solid sub-units, combined with independently one, two or three capsule sub-units. Three or more such sub-units may for example be linearly disposed in the assembled dosage form, e.g. in an arrangement comprising two end sub-units at opposite ends of the line, and one or more intermediate sub-units. For example such an assembled dosage form may comprise a solid sub-unit connected to a capsule compartment; a solid sub-unit between two end capsule compartments; an end capsule compartment, an intermediate capsule compartment and an end solid sub-unit; an end capsule compartment, an intermediate solid sub-unit and an end solid sub-unit; or an intermediate capsule compartment between two end solid sub-units. An assembled dosage of four such sub-units may comprise two end solid sub-units, an intermediate solid sub-unit and an intermediate capsule compartment. Alternately it may comprise two end solid sub-units with two intermediate capsule sub-units, or other combinations of sub-units.

In one embodiment one or more, e.g. all, of the sub-units may for example be substantially cylindrical, which term includes shapes which have a circular, oval or oblate circular cross section across the longitudinal axis, and shapes which have parallel or tapering e.g. with side walls which taper conically over at least part of their extent. Solid sub-units may also be substantially cylindrical in shape. Such substantially cylindrical sub-units may be provided with connectable parts at one or both of their longitudinally disposed ends so that the assembled dosage form may also be overall of a substantially cylindrical shape.

A preferred form of the multi-component dosage form of this invention comprises two capsule compartments.

The invention also provides individual sub-units, e.g. individual capsule compartments or solid sub-units adapted for use in the assembled dosage form.

In the assembled dosage form the adjacent sub-units, whether capsule compartments, solid sub-units or combinations thereof, are connected together by means of a weld at the area where two adjacent parts of the dosage form, e.g. sub-units, are in contact, e.g. a thermal weld, an ultrasonic or inductive weld, or an

5 In thermal, inductive and ultrasonic welding normally localised fusion together of the materials of adjacent parts of the dosage form which are in contact occurs, and on subsequent solidification of the materials a bond is formed between the adjacent parts. An adhesive weld may be achieved by applying an adhesive (e.g. curable adhesives such as UV curable adhesive) to parts of the dosage form which when the dosage form is assembled are in contact, and then causing or allowing the adhesive to set.

The multi-component dosage form of the present invention is particularly suited to fabrication using ultrasonic welding.

- 5 -

Adjacent parts of the dosage form of the invention, e.g. of adjacent sub-units may have features to facilitate the connection of the parts together, particularly to assist or supplement the weld.

For example adjacent parts, e.g. sub-units, of the dosage form of this
5 invention may have substantially planar regions of their surface which may be brought into contact and then the weld may be formed, or may have regions of their surface of complementary, preferably interconnecting shapes, thereby facilitating connecting sub-units together by engagement of these complementary shaped parts.

Preferably, additionally or alternatively adjacent sub-units may be provided
10 with respectively inter-connectable first and second connectable parts such that the first connectable part on one sub-unit may connect with the second connectable part on an adjacent part of the dosage form, e.g. an adjacent sub-unit in a suitable configuration, e.g. in the above-mentioned linear configuration. This interconnection may contribute to the strength of bond achieved by the weld, or
15 additionally or alternatively may help to hold adjacent parts of the dosage form together prior to and in readiness for the weld to be formed and contributes to the retention of the adjacent sub-units together, e.g. via a retaining friction, snap, screw or other kind of fit between the connectable parts. The connectable parts may be such as to facilitate the assembly together of the sub-units in preferred
20 configurations, e.g. the connectable part(s) on one or more one sub-unit may be such as to only connect with a corresponding connectable part on other selected sub-units but not with non-corresponding connectable parts on other sub-units.

Alternatively the connectable parts on the sub-units may be common and interchangeable so that the sub-units may be connected together in a wide range of
25 combinations. This means inter alia that otherwise different capsule compartments or solid sub-units may have mutually connectable parts so that the different capsule compartments or solid sub-units may be connected together in different combinations of solid sub-units or solid sub-units and capsule compartments.

For example in one embodiment the respective first and second connectable
30 parts may be respectively interlocking parts. For example the first or second part may be a socket part, and the corresponding second or first connectable part may be a corresponding plug part which fits into the socket with a retaining friction, snap,

screw or other kind of interlocking fit. If for example these plug and socket parts are common then any plug part on any solid sub-unit or capsule compartment may interconnect with any socket part on another solid sub-unit or capsule compartment.

In a friction fit for example the plug part may be slightly larger than the
 5 socket such that force needs to be applied against the natural resilience and contact friction of the plug and socket parts to cause the plug part to enter the socket, and similar force needs to be applied to separate them. In a snap fit for example the plug and socket parts may be respectively provided with a concavity and a corresponding convexity, such as a ridge and groove, which lock together as the parts are forced
 10 together against the natural resilience of the parts. Such a ridge and groove may for example comprise a co-operating circumferential or part circumferential bead and groove, for example located about the circumference of a connectable plug and socket part.

Above-mentioned US 4576284 and US 4738724 for example, the contents of
 15 which are included herein in their entirety by way of reference, disclose a range of interlocking parts of this general type by means of which capsule compartments may be made to interlock together. See for example Figs. 1, 2 and 3 of US 4576284 which discloses interlocking parts by means of which a cap may be retained on the mouth of a capsule, and Figs. 4 – 43 of US 4738724 which disclose numerous
 20 interlocking parts by means of which part capsule shells may interlock and be retained together as an assembled complete capsule.

The above-described first and second connectable parts facilitate assembly of sub-units together in various ways.

For example in a dosage form of the invention comprising a linear
 25 disposition of three or more e.g. four, sub-units, an intermediate sub-unit may be provided with one or more connectable parts for example one at each end, which may connect with one or more connectable part on an adjacent intermediate sub-unit. An end sub-unit may be provided with one or more connectable part which may connect with a connectable part on an adjacent intermediate sub-unit and/or
 30 with one or more connectable part on another end sub-unit. By means of this two end sub-units may connect together in a dosage form comprising two sub-units, or two end sub-units may be connected to one or more intermediate sub-units. By

using common first and second connectable parts on the sub-units the various end and intermediate sub-units may be made such that they may be connected together in various combinations of assembled dosage forms.

One or more sub-unit which is a capsule compartments may for example be substantially tub-shaped, i.e. having a base closed by a base wall, and side walls extending from the base wall (herein referred to as an "upward" direction), and an upper open mouth. With such a construction capsule compartments may connect together by the base of a first compartment fitting into the open mouth of an adjacent second capsule compartment, so as to close the mouth of the adjacent capsule compartment, and such that the base wall of the first compartment physically separates the compartments. In such a construction the base of the first compartment comprises a plug connectable part, and the mouth opening of the second compartment comprises a socket connectable part.

One or more solid sub-unit may for example be shaped so as to fit as a plug into or a cap over the open mouth of an adjacent capsule compartment so as to function as a closure for the mouth. Alternatively one or more solid sub-unit and the outer surface of the base wall of a capsule compartment may be shaped so as to fit adjacent to and connect with each other. For example the base of such a tub-shaped capsule compartment may be provided externally with a plug or socket part and an adjacent solid sub-unit may be provided externally with a corresponding interconnecting socket or plug part. One or more capsule compartment may be formed with a base part that can connect with the mouth opening of an adjacent capsule compartment so as to function as a closure for the mouth in the above-described manner.

For example the base part of the first compartment may be shaped to engage with an adjacent solid sub-unit, e.g. by forming a socket engagement part on the adjacent part of the solid sub-unit which can engage the base of the capsule compartment. A weld between the sub-units may then be formed in the region of contact e.g. between the base of the first compartment or a solid sub-unit, and the mouth of the second compartment. Additionally or alternatively for example the sub-units may be provided with connectable parts to enable a retaining friction, snap, screw or other kind of interlocking fit.

In such an assembly, a capsule compartment may have its mouth opening closed by the base wall of an adjacent compartment or by part of a solid sub-unit fitting into its open mouth in the manner of a plug closure, or over its mouth opening in the manner of a cap closure.

5 Alternatively a capsule end compartment can be provided with some other type of closure for its mouth opening, particularly if it is connected by its base to an adjacent sub-unit. The closure may for example be made from the same, or a different, polymer than the polymer material of the compartment. This closure may for example comprise an over-cap for example fitting around the outer surface of
10 the side walls of the compartment, as in the general manner disclosed in US 4196565 or US 4250097 or alternatively the closure may comprise a plug type of closure. Above-mentioned US 4576284 discloses some suitable types of closure for capsule compartments which are suitable for use with the present invention. The closure may be retained in place on the mouth opening of its compartment by a
15 weld e.g. as described above, or additionally or alternatively the closure and mouth opening may be provided with features to enable a retaining friction, snap, screw or other kind of interlocking fit.

 Adjacent solid sub-units may for example have respective connectable plug and socket parts which can interlock to connect such adjacent parts together in the
20 assembled dosage form.

 Alternative ways of assembling and connecting the sub-units are encompassed within the scope of the invention.

 For example rather than having an open mouth which is closed by the presence of an adjacent compartment, one or more capsule compartments may be
25 made closed and for example containing the drug substance, and may in this closed form connect in the manner described above with the one or more adjacent sub-units.

 For example one or more capsule compartments may be made in the form of two part compartment shells, each part compartment shell comprising a closed end
30 and side walls and having a mouth opening opposite the closed end, which connect together, e.g. by the means discussed above, with their mouth openings facing, to form the capsule compartment, and one or both of the closed ends may have an

external connectable part. One or both of the closed ends may connect with an adjacent sub-unit, which may be a solid sub-unit or a capsule compartment, e.g. by the means discussed above. For example if the dosage form comprises a linear assembly of sub-units one or both closed ends of an intermediate capsule

- 5 compartment(s) may be connectable to an end sub-unit. For example each end sub-unit may be a substantially tub-shaped capsule compartment as described above and may have a mouth opening that is connectable to the closed end in the manner described above, or may be a solid sub-unit.

For example the dosage form may include one or more linker unit positioned
10 between adjacent pairs of sub-units. At least one weld in the dosage form may be between a sub-unit and such a linker unit. Such a linker unit may for example have connectable parts which are connectable to the above-mentioned first and/or second connectable parts on the adjacent sub-units. Suitably to facilitate a linear assembly of sub-units in the dosage form a linker unit may have its connectable parts in
15 opposite linear facing directions. Suitably such a linker unit may comprise a closure for the mouth opening of a capsule compartment, e.g. connecting with the capsule compartment in the manner of a plug or a cap for its mouth opening, and having a connectable part enabling connection to an adjacent sub-unit, e.g. another capsule compartment.

- 20 In a specific form the linker may have one or two connectable parts which connect with the mouth opening of a capsule compartment. For example such a linker may have two connectable parts which are opposite facing plug parts and which can connect in a plug and socket manner with the mouth opening of two oppositely-facing capsule compartments to thereby form a capsule-linker-capsule
25 assembly. Suitably welds, e.g. ultrasonic welds, may be formed between both of the capsule compartments and the linker between them in such a dosage form.

When for example a capsule compartment has a closure for its mouth opening, then this closure may comprise a linker having one or more first and/or second connectable parts such that the first or second part on the closure may
30 connect with respectively the second or first part on an adjacent sub-unit in a suitable configuration.

For example in one form such a closure may be provide with two oppositely-facing plug connectable parts which can connect with two socket connectable parts on adjacent sub-units, e.g. the mouth openings of opposite-facing capsule compartments. Such a closure can thereby act as a linker between two capsule compartments with their mouth openings oppositely facing, in a capsule compartment – linker – capsule compartment linear arrangement. For example this arrangement may be an end compartment – linker – end compartment arrangement.

Other ways in which such a linker may be used in a dosage form of the invention will be apparent. For example an intermediate capsule compartment may be in the form of a generally cylindrical shape with two oppositely facing open ends, and two linkers may connect via respectively one each of their connectable parts with an open end of the cylinder, leaving the other connectable part available for connection to respectively another sub-unit.

For forming an ultrasonic weld between adjacent parts of the dosage form of this invention, it is preferred that adjacent parts of the dosage form between which the ultrasonic weld is formed, for example of adjacent contacting, capsule compartments and/or solid sub units, or of adjacent contacting parts of a linker and a capsule compartment or solid unit, in particular of end capsule compartments with a linker in between, are profiled and dimensioned to facilitate an ultrasonic shear joint. A shear joint is one type of weld structure which can be used in ultrasonic welding of polymer materials. Adjacent parts to be brought into contact and welded are dimensioned and profiled to provide a small initial contact area, then a controlled interference occurs along the joint as the parts collapse together under the application of ultrasonic energy.

For example a suitable profile is provided by plug and socket connectable parts comprising engaging tenon parts (e.g. opposite facing complementary steps), where the length of one tenon is less than the length of the other tenon part, and under the ultrasonic welding operation the material of the parts can collapse until the tenon parts longitudinally engage.

The multicomponent dosage form of this invention comprising a capsule compartment – linker – capsule compartment in a linear arrangement and connected together by means of at least one ultrasonic weld formed between a capsule

In a preferred construction, the linker comprises a generally cylindrical solid body, its opposite facing ends being plug parts, with two oppositely facing abutment surfaces each being a surface of a ledge formed around the circumference of the cylindrical body and generally planar in a plane perpendicular to the length direction. Such a ledge may typically be ring shaped with its plane perpendicular to the longitudinal direction of the capsule. With such a linker the assembled dosage form may comprise two capsule compartments each in the shape of a cylinder having one open end and one closed end (e.g. the above-described tub or bucket shapes), with their open ends in an opposite facing relationship, with a linker between them with each of the opposite facing plug parts of the linker fitting in a plug-and-socket manner into the open end of a capsule compartment, with an ultrasonic weld formed between a plug part and/or an abutment surface of the linker and the compartment wall in the vicinity of the open end, e.g. the rim of the open end.

Another assembled dosage form may comprise three capsule compartments, two being end compartments each in the shape of a cylinder having one open end and one closed end, with their open ends in an opposite facing relationship, with an intermediate compartment longitudinally between the two end compartments, with a linker between each end compartment and the intermediate compartment and with each of the opposite facing plug parts of the linker fitting in a plug-and-socket manner into the open end of a capsule compartment, with an ultrasonic weld formed between a plug part and/or an abutment surface of the linker and the compartment wall in the vicinity of the open end, e.g. the rim of the open end.

Advantageous features of the linker have also been devised to facilitate assembly and/or ultrasonic welding of the dosage form of this invention.

Preferably the linker is overall in the form of a cylindrical body flattened in its length direction, for example having diameter : length ratios in the range 4 : 1 to 1.5 : 1. The body may have an end surface which is substantially planar over at least 50% of its extent to facilitate ultrasonic welding as such a planar surface is found to assist in the transmission of ultrasonic energy from a welding horn to the area where the ultrasonic weld is to be formed when the plug part of the linker is fitted into the open end. For example such a planar surface may be a ring-shaped

The parts of the dosage form of this invention, e.g. a capsule compartment wall, a solid sub-unit, or a closure or linker as described above may comprise any pharmaceutically acceptable polymer (and adhesive material if adhesive welds are formed) which is generally regarded as safe, e.g. for oral injection and is capable of being formed into the required shape of a capsule compartment wall, a solid sub-unit, or a closure or linker as described above. A preferred method of forming the polymer material into the desired shape is injection moulding, which may be a hot or cold runner injection moulding process. Suitable injection moulding machines for such a process are known.

In the process of injection moulding a fluid polymer is injected under pressure into a precisely made die cavity in a mould block. Injection moulding processes can enable the sub-units to be made with the precision necessary to achieve connection by tight friction-fit or snap-fit interlocking and to maintain suitable contact between adjacent parts to facilitate a weld. Suitable techniques of injection moulding are known from for example the art of manufacture of small plastic components e.g. small parts of LEGO™ toys. Processes such as those described in Cuff. G and Raouf. F (op. cit.) may be used to manufacture such solid sub-units and capsule compartments via injection moulding.

Consequently the invention also provides a moulding process, for example an injection moulding or powder compression process, wherein sub-units, including the solid sub-units and capsule compartments of the dosage form are made in respective mould cavities.

The invention also provides a mould or die, for example an injection mould or powder compression mould or die suitable for use in this moulding process. Such a mould or die may have a mould cavity corresponding to the shape of the sub-unit. Moulds may be made by known metal engraving processes such as spark-erosion, and it is generally preferred to use moulds made from pharmaceutically acceptable metals e.g. steels of the type known for use in tablet compression dyes.

Suitable polymers for the parts of the dosage form of this invention include: polyvinyl alcohol (PVA), natural polymers (such as polysaccharides like pullulan, carrageenan, xanthan, chitosan or agar gums), polyethylene glycols (PEG), polyethylene oxides (PEO), mixtures of PEGs and PEOs,

hydroxypropylmethylcellulose (HPMC), methylcellulose, hydroxyethylcellulose, hydroxyethyl methylcellulose, hydroxypropylcellulose, methacrylic acid copolymer (such as Eudragit E™, Eudragit L™ and/or Eudragit S™), ammonium methacrylate copolymers (such as Eudragit RL™ and/or Eudragit RS™), carboxymethylcellulose, 5 povidone (polyvinyl pyrrolidone), polyglycolysed glycerides (such as Gelucire 44/14™, Gelucire 50/02™, Gelucire 50/13™ and Gelucire 53/10™), carboxyvinyl polymers (such as Carbopols™), polyoxyethylene-polyoxypropylene copolymers (such as Poloxamer 188™).

Acrylic and/or methacrylic acid-based polymers which are soluble in 10 intestinal fluids and which can be formed into capsules are for example disclosed in US 5705189 (Roehm GmbH) the content of which is incorporated herein by reference. The Eudragit™ polymers discussed above for example are extrudable and may for example be plasticised with e.g. triethyl citrate, or glyceryl monostearate.

15 It is also known to form solid bodies suitable for the solid sub-units of this invention using processes of powder compression. For such processes amylose, cross-linked amylose and amylose-pectin combinations may be suitable.

Preferred polymers are orally ingestible polymers and include polyvinyl alcohol, hydroxypropyl methyl cellulose, and other cellulose-based polymers. 20 Preferred polymers also include polymer materials which preferentially dissolve or disintegrate at different points in the digestive tract. Such polymers include the known acrylic and/or methacrylic acid-based polymers which are soluble in intestinal fluids, e.g. the Eudragit™ series of commercially available polymers. Examples of these include Eudragit E™, such as Eudragit E 100™, which 25 preferentially dissolves in the more acid pH of the stomach, or enteric polymers such as Eudragit L™ and/or Eudragit S™ which preferentially dissolve in the more alkaline pH of the intestine, and Preferred polymers also include polymers which dissolve slowly, e.g. a predetermined rate in the digestive tract, such as Eudragit RL™, e.g. Eudragit RL 100™, and/or Eudragit RS™ e.g. Eudragit R100™, and/or 30 blends of such Eudragit™ polymers.

The polymer material(s) may include other substances to modify their properties and to adapt them to various applications, including for example the

following general classes of substances. Surfactants, such as Polysorbate 80™, sodium lauryl sulphate, and Polyoxyl 40™ hydrogenated castor oil. Absorption enhancers, such as Labrasol™, Transcutol™; glidants, such as stearyl alcohol, talc, magnesium stearate, silicon dioxide, amorphous silicic acid, fumed silica,
5 Simeticone™; plasticizers, such as triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, glyceryl monostearate, diethyl phthalate, dibutyl phthalate, propylene glycol, triacetin and castor oil; substances for release modification, such as ethyl cellulose and cellulose acetate phthalate; disintegrants, such as sodium starch glycollate, croscarmellose sodium, crospovidone (cross-
10 linked polyvinyl pyrrolodone), colouring agents, flavouring agents and sweetening agents.

The sub-units may additionally include materials in the polymer materials of which they are made to enhance the ease with which they can be welded together. The sub-units may additionally be provided with constructional features and/or
15 include materials in the polymer materials of which they are made to enhance the ease with which they can be welded together, e.g. opacifier materials such as carbon (e.g. 0.2-0.5%), iron oxides or titanium dioxide (e.g. 0.5-1.0%) to help the polymer to absorb laser energy. Such opacifier materials are generally regarded as safe.

20 For example each of a plurality of sub units, e.g. of capsule compartments, solid sub-units, or combinations thereof may comprise the same or different polymer.

For example each of a plurality of sub units, e.g. of capsule compartments, solid sub-units, or combinations thereof may comprise the same or different drug
25 substance.

For example each sub-unit may contain the same drug substance but releasable in the gastro-intestinal tract of the patient at a different rate, at different times after administration to the patient or at different places in the patient's gastro-intestinal system. Alternatively each sub-unit may contain a different drug
30 substance, each of which may be released at the same or a different rate or time after administration or place in the patient's gastro-intestinal system.

For example two or more sub-units, e.g. two capsule compartments, may each contain different drug substances, and/or different drug substance formulations, and/or the same drug in different formulations, so that a combination of two or more drug substances or formulations may be administered to a patient.

5 The dosage form of this invention enables the assembly together of sub-units which differ in their drug content and/or drug content release characteristics to provide a dosage form tailored to specific administration requirements.

10 The dimensions and shape of each of the sub-units and hence of the overall assembled dosage form may be determined by the nature and quantity of the material to be contained therein and the intended mode of administration and intended recipients. For example a dosage form intended for oral administration may be of a shape and size similar to that of known capsules intended for oral administration.

15 The dosage form is particularly suitable for presentation as an oral dosage form containing one or more drug substances suitable for oral administration, and appears to be suitable for all types of such drug substance.

20 As explained in Cuff G. and Raouf F. (op.cit.), in the matrix of solid sub-units the drug substance may be present in various states. For example it may comprise discrete particles dispersed in the matrix, for example in the case of particles that do not readily dissolve in the fluid polymer. Alternatively the drug substance may be present as a solid solution in the solid polymer of the matrix. Alternatively some of the drug substance may comprise discrete particles and some may be present as a solid solution in the polymer. When two or more solid sub-units are present the drug substance present in each solid sub-unit may be in the same or in different states, e.g. having different drug substance release characteristics.

25 The drug substance(s) contained in any capsule compartment may be present in any suitable, e.g. conventional, form, e.g. as a powder, granules, compact, microcapsules, gel, syrup or liquid provided that the capsule compartment wall material is sufficiently inert to the liquid content of the latter three forms. The contents of the compartments, e.g. drug substances, may be introduced into the

30

compartments by standard methods such as those used conventionally for filling capsules, such as dosating pins or die filling.

The sub-units may differ from each other in their drug content release characteristics, and this may be achieved in various ways.

5 For example one or more solid sub-units and/or capsule compartments may be substantially immediate release, i.e. releasing their drug content substantially immediately upon injection or on reaching the stomach. This may for example be achieved by means of the matrix polymer or the capsule compartment wall dissolving, disintegrating or otherwise being breached to release the drug content
10 substantially immediately. Generally, immediate-release sub-units are preferably provided by being capsule compartments.

 For example one or more solid sub-units and/or capsule compartments may be sustained-release sub-units. Preferably these are solid sub-units, as a bulk matrix of polymer is likely to dissolve or disperse more slowly to release its drug content
15 that a thin walled capsule.

 For example one or more solid sub-units and/or capsule compartments may be pulsed-release sub-units for example releasing their drug content at a specific predetermined point in a patient's gastro-intestinal system. This may be achieved by the use of polymer materials which dissolve or disperse only at defined pH
20 environments, such as the above mentioned Eudragit™ polymers.

 In the case of the above-described linear arrangement of sub-units, suitably one of the end sub-units, particularly a capsule compartment may be a substantially immediate-release compartment, so that the disruption of this end sub-unit has little or no influence on the other sub-units, e.g. the other end sub-unit or the
25 intermediate sub-unit(s), in the assembly. In such a case the other end and the intermediate sub-unit(s) may be delayed or pulse release sub-units, i.e. releasing their drug content at a delayed time after administration. For example in the case of oral administration these delayed release sub-units may release their drug content in the stomach, small or large intestine.

30 For example in the above-described capsule compartment-linker-capsule compartment dosage form one capsule compartment may be effectively immediate release and the other may be sustained, delayed or pulsed release. To achieve this

determine the time of onset and/or rate of release of the drug substance content.

For example such points of weakness may comprise holes, e.g. small holes, e.g. laser-drilled holes in the compartment wall or the closure, these holes being closed and/or covered with a film of a polymer material that dissolves at a pre-determined point in the digestive tract, for example an enteric polymer material. For example such points of weakness may comprise thinned parts in a capsule compartment wall formed during the moulding operation in which the capsule compartment is formed.

The sub-units may additionally or alternatively have surface or other constructional features which modify their drug release characteristics. For example solid sub-units may be provided with internal cavities or channels to create a large surface area. For example solid sub-units may be in the form of hollow cylinders, donuts, or toroids, which shapes are known to tend towards first-order dissolution or erosion in liquid media and correspondingly to tend toward first-order release of drug content dispersed therein.

The invention will now be described by way of example only with reference to:

Fig.1 which shows a longitudinal sectional view of a dosage form of the invention assembled together.

Fig. 2 which shows a longitudinal sectional view of another dosage form of the invention assembled together.

Fig. 3 which shows a longitudinal sectional view of another dosage form of the invention assembled together.

Fig.4 which shows a longitudinal sectional view of a dosage form of the invention assembled together.

Fig. 5 which shows a longitudinal sectional view of another dosage form of the invention assembled together.

Fig. 6 which shows longitudinal and cross sections, and an enlarged part view of another dosage form of the invention.

Fig. 7 which shows an assembly sequence of a dosage form of Fig. 6.

Referring to Fig. 1, a dosage form 11 is shown comprising three sub-units 12, 13, 14 linearly disposed in the assembled dosage form, in an arrangement comprising two end compartments 12, 14 at opposite ends of the line, and one

intermediate solid sub-unit 13. The compartments 12 and 14 and the solid sub-unit 13 are substantially cylindrical. The compartments 12 and 14 are substantially tub-shaped, i.e. each having a base closed by a base wall 12A, 14A, and each having side walls 2B, 4B extending upward from the base wall 12A, 14A, and an upper open mouth. Each of the compartments 12 and 14 is made of polyvinyl alcohol polymer by injection moulding.

The solid sub-unit 13 is also substantially cylindrical, and has its base end 13A formed into a plug shape capable of engaging with and thereby closing the open mouth of either compartment 12 or 14. As shown in Fig. 1 the base end 13A of solid sub-unit 13 fits into and is in engagement with the mouth opening of compartment 14. The upper end of solid sub-unit 13 has its upper end 13B formed into a socket connector capable of engaging with the shape of the base 12A or 14A of capsule compartment 12 or 14, as shown in Fig. 1 being in engagement with the base of compartment 12.

The compartments 12, 14 and solid sub-unit 13 connect together by the base 12A of compartment 12 fitting into the upper socket 13B of adjacent solid sub-unit 13, and the base 12A of the solid sub-unit 13, fitting into the open mouth of adjacent compartment 14 so as to close its mouth. In this assembly of sub-units 12, 13, 14 the base part of an upper sub-unit 12, 13 comprises a plug part and the mouth opening or upper socket of a lower sub-unit respectively 13, 14 comprises a socket.

Compartment 14 is an end compartment 13 and has its mouth opening closed by the base end 13A of solid sub-unit 13. The other upper end compartment 12 is closed by a closure 15 having a plug part 16 which is dimensioned to fit into the mouth opening of the compartment 12.

The base parts 12A and 13A and the plug part 16, fit into the respective mouth openings of the compartments 12 and 14. A thermal weld is formed between the base parts 12A and 13A, the plug part 16, and the respective mouth openings and upper socket of the compartments 12, 14 and the solid sub-unit 13 at the region where these parts are in contact. Each of the base parts 12A, 13A, and the plug part 16, and the corresponding respective mouth openings and upper socket of the compartments 12, 13 and 14 may additionally or alternatively be provided with

features (not shown) such as a convex circumferential bead and a corresponding circumferential groove into which the bead may fit, such that the base part 12A, 13A, the mouth openings of the compartments 12 and 14, the upper socket 13B and the plug part 16 and mouth opening of compartment 12 may connect together by a
5 snap fit interlocking engagement overcoming the natural resilience of the polymer material of the base part and mouth opening.

A thermal weld may be formed between the base parts 12A and 13A, the plug part 16, and the respective mouth openings and upper socket of the compartments 12, 14 and the solid sub-unit 13, by directing a laser beam to the
10 region where these parts are in contact.

The base parts 12A, 13A, 14A of the compartments 12, 13, 14, the mouth openings of the compartments 12 and 14, the upper socket 3B and the plug part 16 are all of common dimensions so that the compartments 12 and 14 and the solid sub-unit may be fitted together in other linear combinations, and so that the plug 15
15 may be used to close the mouth opening of the other compartments 14.

Similarly, two or more than the three sub-units 12, 13 or 14, may be connected together in an analogous manner to that shown in Fig 1.

Fig. 2 shows another dosage form assembly 21. This assembly 21 also comprises three sub-units 22, 23, 24 in a linear assembly of an end compartment
20 22, an intermediate compartment 23 and an end solid sub-unit 24. The intermediate compartment 23 is made in the form of part compartment shells 23A and 23B, each part shell 23A, 23B comprising a closed end 23C and 23D and side walls 23E and 23F with a mouth opening opposite each closed end 23C and 23D. The mouth openings of the two part shells 23A and 23B are each provided respectively with a
25 plug connectable part 25 and a socket connectable part 26. These part shells 23A, 23B connect together with their respective plug and socket parts 25 and 26 connecting to form the capsule compartment 23. Both of the closed ends 23C, 23D are externally provided with connectable parts 27, 28.

The end compartment 22 is in the form of a tub-shaped compartment and has
30 a mouth opening 29, which comprises a socket part that corresponds in shape with connectable part 27 on the intermediate compartment 23 to connect the assembly 21 together.

The end solid sub-unit 24 is formed as a substantially cylindrical body, having a connectable part 210 in the form of a socket engageable with either of the connectable parts 27 or 28 on intermediate capsule compartment 23. As shown in Fig. 2 the connectable part 210 on solid sub-unit 24 is connected to the part 28 on capsule compartment 23.

As with the dosage form of Fig. 1, a thermal weld is formed between the parts 25, 26, 27, 29, 28 and 210 at the region where these parts are in contact. Each of these parts 25, 26, 27, 29, 28 and 210 may additionally or alternatively be provided with features (not shown) such as respectively a convex circumferential bead and a circumferential groove into which the bead may fit, such that these interlocking parts may connect together by a snap fit engagement.

Fig. 3 shows another dosage form assembly 31. This assembly 31 comprises four sub-units 32, 33, 34, 35 in a linear assembly of an end solid sub-unit 32, an intermediate solid sub-unit 33, an intermediate capsule compartment 34 and an end solid sub-unit 35. The intermediate capsule compartment sub-unit 34 has a mouth opening 36, and the immediately adjacent rim 37 of this mouth opening 36 is formed as a plug connectable part. The end solid sub-unit 35 is substantially hemispherical and is formed as a closure cap for the tub-shaped intermediate capsule compartment 34, being formed at its lower end as a socket connectable part 38 which fits in a sealing engagement with the part 37. The closed lower end 34A of compartment 34 is externally provided with a socket connectable part 39.

The intermediate solid sub-unit 33 has its upper end formed as a plug connectable part 310 engageable with the part 39 of the compartment 34, and a lower end formed as a socket connectable part 311.

The end solid sub-unit 32 is in the form of a rounded bottomed cylinder having a plug connectable part 312 part that corresponds in shape with connectable part 311 on the intermediate compartment 33. Each of these parts 37, 38, 39, 310, 311, 312 may additionally or alternatively be provided with features (not shown) such as respectively a convex circumferential bead and a circumferential groove into which the bead may fit, such that these interlocking parts may connect together by a snap fit engagement.

ultrasonic horn (not shown) to the region where these parts are in contact. Each of the base parts 42A, 43A, and the plug part 46, and the corresponding mouth openings of the compartments 43, 44 and 42 may additionally or alternatively be provided with features (not shown) such as a convex circumferential bead and a
5 corresponding circumferential groove into which the bead may fit, such that the base part 42A, 43A and mouth openings of the compartments 43 and 44, and the plug part 46 and mouth opening of compartment 42 may connect together by a snap fit interlocking engagement overcoming the natural resilience of the polymer material of the base part and mouth opening.

10 The base parts 42A, 43A, 44A of the compartments and the mouth openings of the compartments 42, 43, 44, and the plug part 46 are all of common dimensions so that the compartments 42, 43 and 44 may be fitted together in other linear combinations, and so that the plug 45 may be used to close the mouth opening of any of the other compartments 42, 43 or 44.

15 Similarly, two or more than the three compartments 42, 43 or 44, may be connected together in an analogous manner to that shown in Fig 4.

Fig. 5 shows another dosage form assembly 51. This assembly 51 also comprises three compartments 52, 53, 54 in a linear assembly of two end compartments 52, 54 and an intermediate compartment 53. The intermediate
20 compartment 53 is made in the form of part compartment shells 53A and 53B, each part shell 53A, 53B comprising a closed end 53C and 53D and side walls 53E and 53F, with a mouth opening opposite the closed end. The mouth openings of the two part shells 53A and 53B are each provided respectively with a plug connectable part 55 and a socket connectable part 56. These part shells 53A, 53B connect together
25 with their respective plug and socket parts 55 and 56 connecting to form the capsule compartment 53. Both of the closed ends 53C, 53D are externally provided with connectable plug parts 57, 58.

Each end compartment 52, 54 is in the form of a tub-shaped compartment and has a mouth opening, e.g. 59 being that of compartment 52, which comprises a
30 socket part that corresponds in shape with the connectable plug parts 57, 58 on the intermediate compartment 53 to connect the assembly 51 together.

As with the dosage form of Fig. 4, a weld is formed between the parts 55, 56, 57, 58 and the respective mouth openings of the compartments 52, 54, by the application of local heating or an ultrasonic horn (not shown) to the region where these parts are in contact. Each of these parts 55, 56, 57, 58 and the respective
5 mouth openings of the compartments 52, 54 may additionally or alternatively be provided with features (not shown) such as respectively a convex circumferential bead and a circumferential groove into which the bead may fit, such that these interlocking parts may connect together by a snap fit engagement.

Each of the compartments 42, 43, 44, 52, 54 in Figs 4 and 5 may be made
10 of the same or different polymer and may have the same or different drug release characteristics. The intermediate compartments respectively of Figs. 1 and 2 are more suitable for a modified release compartment, as dissolution or disruption of the end compartments 2, 4, 7 and 9 before the intermediate compartments 3 and 8 can occur without disturbance of these intermediate compartments.

Each of the compartments 42, 43, 44, 53, 54 and 55 in Figs 4 and 5 contains
15 the same or different drug substance and/or formulation. This may for example be in the form of powder, granulates, or other solid forms. Alternatively the compartments may contain liquid, gel etc. formulations (not shown).

Fig. 6 shows another dosage form assembly 61. As shown in the
20 longitudinal section Fig. 6A and the cross section Fig. 6B this comprises an assembly of an end capsule compartment 62 – linker 63 – end capsule compartment 64 in a linear arrangement. Each end compartment 62, 64 is suitably in the shape of a cylinder having one open end and one closed end. The closed end is in the form of a generally hemispherical end wall, forming an open ended “bucket” or “tub”
25 shape. The side walls of each capsule compartment taper gently in a shallow conical fashion, the cross section being greatest at the open end. The central part 65 of the rounded end of each compartment 62, 64 is flattened over at least 5% of the end surface area to facilitate the application of ultrasonic energy during the welding operation. The wall of each capsule compartment 62, 64 is ca. 0.4 ± 0.05 mm thick
30 in the cylindrical side walls of the compartment.

The “linker” 63 is provided in the form of a solid wall with oppositely facing surfaces 66, 67 extending generally transverse to the longitudinal direction of

WO 01/08666

PCT/EP00/07295

the linker, being the end surfaces of oppositely facing plug connectable parts 68, 69 formed at each of its longitudinal ends. The linker 63 is a generally cylindrical body flattened in its length direction with a diameter : length ratio ca. 3 : 1. In a specific embodiment the diameter of the linker 63 is ca 7.5 mm, and its length ca. 3.0 mm.

5 The end surfaces 66, 67 are substantially planar over at least 50% of their extent to facilitate application of ultrasonic energy thereto in the welding operation. The planar surface 66, 67 is a ring-shaped surface surrounding a central concavity 610 on each face, in which is the residue 611 of the injection moulding runner. The planar surface 66, 67 extends continuously over a dimension of at least 2 mm, i.e.
10 having a surface area of at least 4mm². Each plug part 68, 69 is a snug friction fit into the open end of a capsule compartment 62, 64. Each plug part 68, 69 is provided with an abutment surface 612 each being a surface of a ledge formed around the circumference of the cylindrical body 63. The ledge 612 is ring shaped with its plane perpendicular to the longitudinal direction of the capsule. The ledge
15 612 defines and limit the extent to which each plug part 68, 69 can extend into the open end of a capsule compartment 62, 64 by abutting against the rim of the open end of a capsule compartment 62, 64. In the specific embodiment the ledge 612 is ca 0.3 mm wide in the direction across the length direction.

An ultrasonic weld is formed between each plug part 68, 69 and/or an
20 abutment surface 612 of the linker 63 and the compartment wall 62, 64 in the vicinity of the open end, e.g. the rim of the open end. The lower compartment 64 is shown formed in this way, the upper compartment 62 being shown disassembled.

For forming an ultrasonic weld between adjacent contacting parts of the capsule compartments 62, 64 and the linker 63 these parts are profiled and
25 dimensioned to facilitate an ultrasonic shear joint, as shown enlarged in Fig. 6C. The plug 68 and socket 613 connectable parts comprise interlocking tenon parts 614, 615, where the length of one tenon 614 (D1 ca. 0.2-0.3 mm) is less than the length (D2 ca. 0.5-0.6 mm) of the other tenon part 615, and under the ultrasonic welding operation the material of the capsule compartment 62 in the region 616 can
30 collapse until the tenon parts longitudinally engage to form the ultrasonic weld between the capsule compartment 62 and the linker 63. The weld between the linker 63 and the compartment 64 has been formed in a similar manner.

The length D2 of the plug part, being ca. 0.55 mm, is ca. 20% of the overall length of the linker 63 between the end surfaces 66 and 67.

Fig. 7 shows a typical assembly procedure for a dosage form of Fig. 6. This comprises the following steps:

- 5 (1) a first capsule compartment 64 is positioned and supported in a suitable holding means with its mouth opening pointing upwards, and the capsule compartment 64 is filled with a suitable quantity of a drug substance.
- (2) a first plug part 69 of a linker 63 is inserted into the open end of the first capsule compartment 64. In this manner the linker 63 forms a closure for the mouth
10 opening of the capsule compartment 64.
- (3) a downwardly pointing ultrasonic horn (not shown) is applied to the surface 66 of the linker 63, i.e. to the opposite surface to that of the first plug part 69, and an ultrasonic weld between the linker 63 and the first capsule compartment 64 is formed.
- 15 (4) the formed assembly of first capsule compartment 64 and linker 63 is inverted so that the plug part 68 is pointing downwards.
- (5) a second capsule compartment 62 is positioned and supported in a suitable holding means (not shown) with its mouth opening pointing upwards, in a manner analogous to step 1, and the second compartment 62 is filled with a suitable quantity
20 of drug substance.
- (6) The opposite, second, plug part 68 of the linker 63 is inserted into the open end of the second capsule compartment 62
- (7) an ultrasonic horn (not shown) is applied to the outer surface of the second compartment 62 from underneath. An ultrasonic weld is formed between the linker
25 63 and the second capsule compartment 62.

In an alternative welding mode shown (8) an ultrasonic horn (not shown) is applied laterally as shown by the arrow to the side of the region of contact between the capsule compartment 64 and the linker 63.

In other alternative modes (not shown) thermal, laser or adhesive welds may
30 be formed between the capsule compartments 62 and 64 and the linker 63.

Each of the compartments and sub-units in Figs. 1 to 6 may be made of the same or different polymer and may have the same or different drug release

characteristics. The intermediate capsule compartments are more suitable for a modified release compartment, as dissolution or disruption of the end compartments before the intermediate compartments can occur without disturbance of these intermediate compartments.

5 The solid sub-units are more suitable as a sustained release sub-unit, as the dissolution of the matrix polymer is likely to occur more slowly than the disruption of the thin wall of a capsule compartment. The hollow bore of unit 313 gives the solid unit 313 a dissolution rate tending toward first-order dissolution kinetics.

10 Each of the sub-units 12, 13, 14, 22, 23, 24, 32, 33, 34, 35 may contain the same or different drug substance and/or formulation. This may for example be in the form of powder, granulates, or other solid forms. Alternatively the capsule compartments 12, 14, 22, 34 may contain liquid, gel etc. formulations (not shown). The end sub-unit 35 may contain a drug substance or alternately may simply comprise a solid polymer cap devoid of drug substance.

Claims:

1. A multi-component pharmaceutical dosage form is provided which
5 comprises a plurality of drug substance – containing sub-units each selected from capsule compartments which can release their drug substance in the gastro-intestinal environment, and solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the polymer being soluble, dispersible or disintegrable in the patient's gastro-intestinal environment to thereby release the drug substance, the
10 sub-units being connected together in the assembled dosage form and being retained together by the connection at least prior to administration to a patient, wherein the connection is provided by a weld between parts of the assembled dosage form.
2. A dosage form according to claim 1 characterised by common
interchangeable interconnectable parts so that the sub-units may be assembled in
15 various combinations using the same basic units of capsule compartments, solid sub-units or of solid sub-units and capsule compartments.
3. A dosage form according to claim 1 or 2 characterised in that the dosage form comprises a plurality of capsule compartments each bounded and physically separated from at least one adjacent compartment by a wall made of a
20 pharmaceutically acceptable polymer material, adjacent compartments being connected together in the assembled dosage form and being retained together by the connection at least prior to administration to a patient, one or more of the compartments containing a drug substance, and wherein the connection is provided by a weld between parts of the assembled dosage form.
- 25 4. A dosage form according to claim 3 characterised by two such capsule compartments.
5. A dosage form according to claim 1 or 2 characterised in that the pharmaceutical dosage form comprises a plurality of drug-containing sub-units connected together in the assembled dosage form and being retained together by the
30 connection at least prior to administration to a patient, at least one of the sub-units being a solid sub-unit comprising a solid matrix of a polymer which contains a drug substance, the polymer being soluble, dispersible or disintegrable in the patient's

gastro-intestinal environment to thereby release the drug substance, and wherein the connection is provided by a weld between parts of the assembled dosage form.

6. A dosage form according to claim 5 characterised in that one or more of the sub-units comprise a solid sub-unit, and one or more of the other sub-units comprise
- 5 a capsule compartment bounded by a wall made of a pharmaceutically acceptable polymer material, one or more of the said capsule compartments containing a drug substance.
7. A dosage form according to any one of the preceding claims characterised in that the weld is a thermal weld, an inductive weld, or an adhesive weld.
- 10 8. A dosage form according to any one of claims 1 to 6 characterised in that the weld is an ultrasonic weld.
9. A dosage form according to any one of the preceding claims characterised in that adjacent parts of the dosage form of the invention have constructional features to facilitate the connection of the parts together, particularly to assist or supplement
- 15 the weld.
10. A dosage form according to any one of the preceding claims characterised in that adjacent sub-units are provided with respectively inter-connectable first and second connectable parts such that the first connectable part on one sub-unit may connect with the second connectable part on an adjacent part of the dosage form.
- 20 11. A dosage form according to claim 10 characterised in that one or more sub-unit is a capsule compartments and is substantially tub-shaped having a base closed by a base wall, and side walls extending upward from the base wall, and an upper open mouth, and the mouth opening comprises a socket connectable part.
12. A dosage form according to claim 10 characterised in that one or more solid
- 25 sub-unit is so shaped as to fit as a plug into or a cap over the open mouth of an adjacent capsule compartment so as to function as a closure for the mouth.
13. A dosage form according to claim 10 characterised in that one or more solid sub-unit and the outer surface of the base wall of a capsule compartment are so shaped so as to fit adjacent to and connect with each other
- 30 14. A dosage form according to claim 10 characterised in that one or more capsule compartment is formed with a base part that can connect with the mouth

23. A dosage form according to claim 22 characterised by comprising a capsule compartment – linker – capsule compartment in a linear arrangement and connected together by means of at least one ultrasonic weld formed between a capsule compartment and the linker.
- 5 24. A dosage form according to claim 23 characterised in that the wall of the capsule compartment is preferably ca. 0.3 – 0.5 mm, thick.
25. A dosage form according to claim 23 characterised in that the end compartments are each in the shape of a cylinder having one open end and one end closed by a generally hemispherical end wall, the side walls taper gently in a
- 10 shallow conical fashion, the cross section being greatest at the open end, and the central part of the rounded closed end is flattened to facilitate the application of ultrasonic energy during the welding operation.
26. A dosage form according to any one of claims 16 to 25 characterised in that at least one of the connectable parts of the linker is a plug part which fits in a plug-
- 15 and-socket manner into the open end of a capsule compartment.
27. A dosage form according to claim 26 characterised in that the linker is in the form of a solid wall with oppositely facing plug connectable parts.
28. A dosage form according to claim 26 or 27 characterised in that each plug part is provided with an abutment surface to define and limit the extent to which
- 20 each plug part can extend into the open end of a capsule compartment by abutting against the rim of the open end of a capsule compartment when the plug part extends to a suitable extent into the capsule mouth.
29. A dosage form according to claim 28 characterised in that the linker comprises a generally cylindrical solid body, its opposite facing ends being plug
- 25 parts, with two oppositely facing abutment surfaces each being a surface of a ledge formed around the circumference of the cylindrical body.
30. A dosage form according to any one of claims 16 to 29 characterised in that the linker is overall in the form of a cylindrical body flattened in its length direction and having diameter : length ratios in the range 4 : 1 to 1.5 : 1, with an end surface
- 30 which is substantially planar over at least 50% of its extent.
31. A dosage form according to any one of claims 16 to 30 characterised by a capsule compartment wall in the shape of a cylinder having one open end and one

closed end, and at least 5% of the outer surface of the closed end is substantially planar.

32. A dosage form according to any one of the preceding claims characterised by parts made of a pharmaceutically acceptable polymer which is generally regarded
5 as safe for oral injection and is capable of being formed into the required shape.

33. A dosage form according to any one of the preceding claims characterised in that one or more solid sub-units and/or capsule compartments are substantially immediate release.

34. A dosage form according to any one of the preceding claims characterised in
10 that one or more solid sub-units and/or capsule compartments are sustained release or pulsed release.

35. A dosage form according to any one of the preceding claims characterised by two or more capsule compartments which differ in thickness between
15 compartments so that thicker walled compartments disrupt more slowly than thinner walled compartments.

36. A dosage form according to any one of the preceding claims characterised by one or more capsule compartments which have areas or points of weakness which preferentially dissolve.

37. A process for manufacturing a dosage form according to any one of the
20 preceding claims which comprises a capsule compartment - linker - capsule compartment in a linear arrangement, characterised by the steps of first filling a first capsule compartment with a suitable quantity of drug substance; insertion of a first plug part of a linker into the open end of the first capsule compartment and welding this in place; filling a second capsule compartment containing a suitable
25 quantity of drug substance; insertion of the opposite, second, plug part of the linker into the open end of the second capsule compartment and welding the linker and second capsule compartment together.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 February 2001 (08.02.2001)

PCT

(10) International Publication Number
WO 01/08666 A1

(51) International Patent Classification⁷: **A61K 9/48**

(21) International Application Number: PCT/EP00/07295

(22) International Filing Date: 27 July 2000 (27.07.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

9917772.7	30 July 1999 (30.07.1999)	GB
9917774.3	30 July 1999 (30.07.1999)	GB
9917775.0	30 July 1999 (30.07.1999)	GB
9917777.6	30 July 1999 (30.07.1999)	GB

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CLARKE, Allan, J.** [US/US]; SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406 (US); **FO-NIO, Teodoro** [IT/IT]; SmithKline Beecham S.p.A., Via Zambelletti, I-20021 Baranzate di Bollate (IT); **HARRIS, Geoffrey, Arthur** [GB/GB]; SmithKline Beecham Pharmaceuticals, Clarendon Road, Worthing, west Sussex BN14 8QH (GB); **KIFT, Ronald** [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB); **LIGHTFOOT, Donald** [US/US]; SmithKline Beecham Pharmaceuticals, 1250 South collegeville Road, P.O. Box 5089, Collegeville, PA 19426-0989 (US); **MCGINLEY, Shane** [US/US]; SmithKline Beecham Pharmaceuticals,

1250 South Collegeville Road, P.O. Box 5089, Collegeville, PA 19426-0989 (US); **OFSHARICK, Thomas** [US/US]; SmithKline Beecham Pharmaceuticals, 1250 South Collegeville Road, P.O. Box 5089, Collegeville, PA 19426-0989 (US); **SZYMCAK, Margaret, Mary** [US/US]; SmithKline Beecham Pharmaceuticals, One Franklin Plaza, Philadelphia, PA 19103 (US).

(74) Agent: **WALKER, Ralph, Francis**; SmithKline Beecham Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MULTI-COMPONENT PHARMACEUTICAL DOSAGE FORM

(57) Abstract: A multi-component pharmaceutical dosage form comprising a plurality of drug substance - containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.

WO 01/08666 A1

1/5

Fig.1.





Fig.2.



2/5




Fig.4.




Fig.5.




Fig.6A.




Fig.6B.




Fig.6C.





Fig.7.



DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

MULTI-COMPONENT PHARMACEUTICAL DOSAGE FORM

the specification of which (check one)

- ☐ is attached hereto.
☒ was filed on 27 July 2000 as Serial No. PCT/EP00/07295
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			
Number	Country	Filing Date	Priority Claimed
9917772.7	Great Britain	30 July 1999	Yes
9917774.3	Great Britain	30 July 1999	Yes
9917775.0	Great Britain	30 July 1999	Yes
9917777.6	Great Britain	30 July 1999	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to Dara Dinner, GlaxoSmithKline, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-5017.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: ¹⁻⁰ Allan J CLARKE

Inventor's Signature: *Allan J Clarke* Date: 12 AUG 2002

Residence: King of Prussia, Pennsylvania, US PA

Citizenship: American

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

²⁻⁰ Full Name of Inventor: Teodoro FONIO

Inventor's Signature: X *Teodoro Fonio* Date: X 29 APRIL 2002

Residence: Arese, Italy

Citizenship: Italian

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939 PA

30
Full Name of Inventor: Geoffrey Arthur HARRIS

Inventor's Signature: X G Harris

Date: X 18/6/02

Residence: Worthing, West Sussex, GB

Citizenship: British

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939 PA

40
Full Name of Inventor: Ron KIFT

Inventor's Signature: X R Kift

Date: X 10/5/02

Residence: Harlow, Essex, GB GB

Citizenship: British

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

50
Full Name of Inventor: Donald LIGHTFOOT

Inventor's Signature: Donald Lightfoot

Date: 26 Aug 2002

Residence: Collegeville, Pennsylvania, US PA

Citizenship: American

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

60
Full Name of Inventor: Shane McGINLEY

Inventor's Signature: Shane McGinley

Date: 03 Sep 2002

Residence: Collegeville, Pennsylvania, US PA

Citizenship: American

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

70
Full Name of Inventor: Thomas OFSHARICK

Inventor's Signature: Thomas Ofsarick

Date: 28 AUG 2002

Residence: Collegeville, Pennsylvania, US PA

Citizenship: American

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

80
Full Name of Inventor: Margaret Mary SZYMCZAK

Inventor's Signature: Margaret Mary Szymczak

Date: 24 July 2002

Residence: Philadelphia, Pennsylvania, US PA

Citizenship: American

Post Office Address: GlaxoSmithKline
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939